Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan.

Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian A, Grey ST, Da Silva A, Leung W; Australian Pancreatic Genome Initiative (APGI), Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips PA, Whitelock JM, Gill AJ, Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR, Timpson P.

Nat Commun. 2019 Aug 12;10(1):3637. doi: 10.1038/s41467-019-10968-6.

2.

Morphogenesis of extra-embryonic tissues directs the remodelling of the mouse embryo at implantation.

Christodoulou N, Weberling A, Strathdee D, Anderson KI, Timpson P, Zernicka-Goetz M.

Nat Commun. 2019 Aug 7;10(1):3557. doi: 10.1038/s41467-019-11482-5.

3.

Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy.

Parkin A, Man J, Timpson P, Pajic M.

FEBS J. 2019 Jul 22. doi: 10.1111/febs.15011. [Epub ahead of print] Review.

PMID:
31330086
4.

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O'Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR.

Breast Cancer Res. 2019 Mar 21;21(1):43. doi: 10.1186/s13058-019-1127-y.

5.

ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling.

Pinho AV, Van Bulck M, Chantrill L, Arshi M, Sklyarova T, Herrmann D, Vennin C, Gallego-Ortega D, Mawson A, Giry-Laterriere M, Magenau A, Leuckx G, Baeyens L, Gill AJ, Phillips P, Timpson P, Biankin AV, Wu J, Rooman I.

Nat Commun. 2018 Nov 30;9(1):5083. doi: 10.1038/s41467-018-07497-z.

6.

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma.

Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M.

Diseases. 2018 Nov 13;6(4). pii: E103. doi: 10.3390/diseases6040103. Review.

7.

Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.

Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P.

Gut. 2019 Apr;68(4):742-758. doi: 10.1136/gutjnl-2018-316822. Epub 2018 Nov 5. Review.

8.

Recent advances in understanding the complexities of metastasis.

Chitty JL, Filipe EC, Lucas MC, Herrmann D, Cox TR, Timpson P.

Version 2. F1000Res. 2018 Aug 1 [revised 2018 Jan 1];7. pii: F1000 Faculty Rev-1169. doi: 10.12688/f1000research.15064.2. eCollection 2018. Review.

9.

CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer.

Kalimutho M, Sinha D, Jeffery J, Nones K, Srihari S, Fernando WC, Duijf PH, Vennin C, Raninga P, Nanayakkara D, Mittal D, Saunus JM, Lakhani SR, López JA, Spring KJ, Timpson P, Gabrielli B, Waddell N, Khanna KK.

EMBO Mol Med. 2018 Sep;10(9). pii: e8566. doi: 10.15252/emmm.201708566.

10.

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.

Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng N, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, Timpson P, O'Toole S, Watkins DN, Cox TR, Samuel MS, Martín M, Swarbrick A.

Nat Commun. 2018 Jul 24;9(1):2897. doi: 10.1038/s41467-018-05220-6.

11.

Removing physiological motion from intravital and clinical functional imaging data.

Warren SC, Nobis M, Magenau A, Mohammed YH, Herrmann D, Moran I, Vennin C, Conway JR, Mélénec P, Cox TR, Wang Y, Morton JP, Welch HC, Strathdee D, Anderson KI, Phan TG, Roberts MS, Timpson P.

Elife. 2018 Jul 9;7. pii: e35800. doi: 10.7554/eLife.35800.

12.

Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.

Conway JRW, Warren SC, Herrmann D, Murphy KJ, Cazet AS, Vennin C, Shearer RF, Killen MJ, Magenau A, Mélénec P, Pinese M, Nobis M, Zaratzian A, Boulghourjian A, Da Silva AM, Del Monte-Nieto G, Adam ASA, Harvey RP, Haigh JJ, Wang Y, Croucher DR, Sansom OJ, Pajic M, Caldon CE, Morton JP, Timpson P.

Cell Rep. 2018 Jun 12;23(11):3312-3326. doi: 10.1016/j.celrep.2018.05.038.

13.

MASTL overexpression promotes chromosome instability and metastasis in breast cancer.

Rogers S, McCloy RA, Parker BL, Gallego-Ortega D, Law AMK, Chin VT, Conway JRW, Fey D, Millar EKA, O'Toole S, Deng N, Swarbrick A, Chastain PD, Cesare AJ, Timpson P, Caldon CE, Croucher DR, James DE, Watkins DN, Burgess A.

Oncogene. 2018 Aug;37(33):4518-4533. doi: 10.1038/s41388-018-0295-z. Epub 2018 May 10.

14.

Evidence that TLR4 Is Not a Receptor for Saturated Fatty Acids but Mediates Lipid-Induced Inflammation by Reprogramming Macrophage Metabolism.

Lancaster GI, Langley KG, Berglund NA, Kammoun HL, Reibe S, Estevez E, Weir J, Mellett NA, Pernes G, Conway JRW, Lee MKS, Timpson P, Murphy AJ, Masters SL, Gerondakis S, Bartonicek N, Kaczorowski DC, Dinger ME, Meikle PJ, Bond PJ, Febbraio MA.

Cell Metab. 2018 May 1;27(5):1096-1110.e5. doi: 10.1016/j.cmet.2018.03.014. Epub 2018 Apr 19.

15.

Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth.

Rath N, Munro J, Cutiongco MF, Jagiełło A, Gadegaard N, McGarry L, Unbekandt M, Michalopoulou E, Kamphorst JJ, Sumpton D, Mackay G, Vennin C, Pajic M, Timpson P, Olson MF.

Cancer Res. 2018 Jun 15;78(12):3321-3336. doi: 10.1158/0008-5472.CAN-17-1339. Epub 2018 Apr 18.

16.

Molecular mobility and activity in an intravital imaging setting - implications for cancer progression and targeting.

Nobis M, Warren SC, Lucas MC, Murphy KJ, Herrmann D, Timpson P.

J Cell Sci. 2018 Mar 6;131(5). pii: jcs206995. doi: 10.1242/jcs.206995. Review.

17.

Shedding new light on RhoA signalling as a drug target in vivo using a novel RhoA-FRET biosensor mouse.

Nobis M, Herrmann D, Warren SC, Strathdee D, Cox TR, Anderson KI, Timpson P.

Small GTPases. 2018 Mar 21:1-8. doi: 10.1080/21541248.2018.1438024. [Epub ahead of print]

PMID:
29457531
18.

Acute compressive stress activates RHO/ROCK-mediated cellular processes.

Boyle ST, Kular J, Nobis M, Ruszkiewicz A, Timpson P, Samuel MS.

Small GTPases. 2018 Feb 17:1-17. doi: 10.1080/21541248.2017.1413496. [Epub ahead of print]

PMID:
29455593
19.

∆133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling.

Campbell H, Fleming N, Roth I, Mehta S, Wiles A, Williams G, Vennin C, Arsic N, Parkin A, Pajic M, Munro F, McNoe L, Black M, McCall J, Slatter TL, Timpson P, Reddel R, Roux P, Print C, Baird MA, Braithwaite AW.

Nat Commun. 2018 Jan 17;9(1):254. doi: 10.1038/s41467-017-02408-0.

20.

Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer.

Vennin C, Murphy KJ, Morton JP, Cox TR, Pajic M, Timpson P.

Gastroenterology. 2018 Mar;154(4):820-838. doi: 10.1053/j.gastro.2017.11.280. Epub 2017 Dec 26. Review.

PMID:
29287624

Supplemental Content

Loading ...
Support Center